Search Results - "Beck, LA"

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy by La-Beck, Ninh M., Jean, Gary W., Huynh, Cindy, Alzghari, Saeed K., Lowe, Devin B.

“…The treatment of cancer has largely relied on killing tumor cells with nonspecific cytotoxic therapies and radiotherapy. This approach, however, has…”
Get full text

Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin by Petersen, Grant H., Alzghari, Saeed K., Chee, Wayne, Sankari, Sana S., La-Beck, Ninh M.

“…While liposome-mediated delivery of cytotoxic chemotherapy has been shown to significantly enhance drug tolerability in patients as compared to the…”
Get full text

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions by Anchordoquy, Thomas J, Barenholz, Yechezkel, Boraschi, Diana, Chorny, Michael, Decuzzi, Paolo, Dobrovolskaia, Marina A, Farhangrazi, Z. Shadi, Farrell, Dorothy, Gabizon, Alberto, Ghandehari, Hamidreza, Godin, Biana, La-Beck, Ninh M, Ljubimova, Julia, Moghimi, S. Moein, Pagliaro, Len, Park, Ji-Ho, Peer, Dan, Ruoslahti, Erkki, Serkova, Natalie J, Simberg, Dmitri

“…Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in…”
Get full text

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines by Trinh, Saralinh, Le, Alex, Gowani, Sajida, La-Beck, Ninh

“…Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death-1 protein/programmed cell death ligand 1…”
Get full text

Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine by La-Beck, Ninh M, Islam, Md Rakibul, Markiewski, Maciej M

“…Nanoparticle-based anticancer medications were first approved for cancer treatment almost 2 decades ago. Patients benefit from these approaches because of the…”
Get full text

Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer by La‐Beck, Ninh M., Nguyen, Dung T., Le, Alex D., Alzghari, Saeed K., Trinh, Saralinh T.

“…The rapidly expanding repertoire of immune checkpoint inhibitors (ICIs) now includes two agents, pembrolizumab and atezolizumab, approved for first‐line…”
Get full text

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy by La-Beck, Ninh M, Gabizon, Alberto A

“…The development of stable and long-circulating liposomes provides protection of the drug cargo from degradation and increases tumor drug delivery, leading to…”
Get full text

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment by La-Beck, Ninh M., Liu, Xinli, Shmeeda, Hilary, Shudde, Claire, Gabizon, Alberto A.

“…Amino-bisphosphonates (N-BPs) have been commercially available for over four decades and are used for the treatment of osteoporosis, Paget’s disease,…”
Get full text

Translational considerations in nanomedicine: The oncology perspective by Gabizon, Alberto A., de Rosales, Rafael T.M., La-Beck, Ninh M.

“…Nanoparticles can provide effective control of the release rate and tissue distribution of their drug payload, leading to major pharmacokinetic and…”
Get full text

Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery by La-Beck, Ninh M, Liu, Xinli, Wood, Laurence M

“…Liposomal nanoparticles are a heterogeneous group of engineered drug carriers that have tremendous therapeutic potential in the treatment of cancer. They…”
Get full text

Immune Implications of Cholesterol-Containing Lipid Nanoparticles by Back, Patricia Ines, Yu, Minzhi, Modaresahmadi, Shadan, Hajimirzaei, Sahelosadat, Zhang, Qisheng, Islam, Md Rakibul, Schwendeman, Anna A., La-Beck, Ninh M.

“…The majority of clinically approved nanoparticle-mediated therapeutics are lipid nanoparticles (LNPs), and most of these LNPs are liposomes containing…”
Get full text

Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy by La-Beck, Ninh M., Owoso, Jesuwapelumi

“…The rapidly expanding class of therapies targeting immune checkpoints for the treatment of various cancers now includes 8 clinically approved agents: a…”
Get full text

The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta‐Analysis of Randomized Clinical Trials by Gibson, Jean‐Marie, Alzghari, Saeed, Ahn, Chul, Trantham, Holly, La‐Beck, Ninh M.

“…Learning Objectives Determine circumstances under which ovarian cancer patients would benefit from carboplatin plus pegylated liposomal doxorubicin rather than…”
Get full text

TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species-Dependent Cell Signaling Alterations by Silwal, Ashok, Reese, Britney, Patel, Bhaumik, Li, Yan, Kolev, Martin V, La-Beck, Ninh M, Karbowniczek, Magdalena M, Markiewski, Maciej M

“…The role of the most common TP53 single-nucleotide polymorphism (SNP) at codon 72, which encodes for proline (P72) or arginine (R72), in the regulation of the…”
Get full text

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy by Gabizon, Alberto A, Patil, Yogita, La-Beck, Ninh M

“…Abstract We herein review various pharmacological and clinical aspects of pegylated liposomal doxorubicin (PLD), the first nanomedicine to be approved for…”
Get full text

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate by Rajan, Robin, Sabnani, Manoj K., Mavinkurve, Vikram, Shmeeda, Hilary, Mansouri, Hossein, Bonkoungou, Sandrine, Le, Alexander D., Wood, Laurence M., Gabizon, Alberto A., La-Beck, Ninh M.

“…Liposomal nanoparticles are the most commonly used drug nano-delivery platforms. However, recent reports show that certain pegylated liposomal nanoparticles…”
Get full text

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients by Golan, Talia, Grenader, Tal, Ohana, Patricia, Amitay, Yasmine, Shmeeda, Hilary, La‐Beck, Ninh M., Tahover, Esther, Berger, Raanan, Gabizon, Alberto A.

“…Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use. In animals, pegylated liposomal mitomycin C lipid‐based prodrug…”
Get full text

Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions by Anchordoquy, Thomas, Artzi, Natalie, Balyasnikova, Irina V., Barenholz, Yechezkel, La-Beck, Ninh M., Brenner, Jacob S., Chan, Warren C. W., Decuzzi, Paolo, Exner, Agata A., Gabizon, Alberto, Godin, Biana, Lai, Samuel K., Lammers, Twan, Mitchell, Michael J., Moghimi, S. Moein, Muzykantov, Vladimir R., Peer, Dan, Nguyen, Juliane, Popovtzer, Rachela, Ricco, Madison, Serkova, Natalie J., Singh, Ravi, Schroeder, Avi, Schwendeman, Anna A., Straehla, Joelle P., Teesalu, Tambet, Tilden, Scott, Simberg, Dmitri

“…In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple…”
Get full text

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses by Sabnani, Manoj K., MS, Rajan, Robin, MS, Rowland, Bradley, BS, Mavinkurve, Vikram, MS, Wood, Laurence M., PhD, Gabizon, Alberto A., MD, PhD, La-Beck, Ninh M., PharmaD

“…Abstract Liposomes have tremendous potential as drug carriers in the treatment of cancer. However, despite enhanced tumor drug delivery and decreased toxicity,…”
Get full text

Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model by Islam, Md. Rakibul, Patel, Jalpa, Back, Patricia Ines, Shmeeda, Hilary, Kallem, Raja Reddy, Shudde, Claire, Markiewski, Maciej, Putnam, William C, Gabizon, Alberto A, La-Beck, Ninh M

“…While tumor-associated macrophages (TAM) have pro-tumoral activity, the ablation of macrophages in cancer may be undesirable since they also have anti-tumoral…”
Get full text